European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Veanibek (previously Miglustat Gen.Orph), miglustat, Date of authorisation: 09/11/2017, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 16:35

Human medicines European public assessment report (EPAR): Veanibek (previously Miglustat Gen.Orph), miglustat, Date of authorisation: 09/11/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Vlustozik (previously Ibuprofen Gen.Orph), ibuprofen, Date of authorisation: 16/02/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 16:26

Human medicines European public assessment report (EPAR): Vlustozik (previously Ibuprofen Gen.Orph), ibuprofen, Date of authorisation: 16/02/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 16:18

Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Sycrest, asenapine, Date of authorisation: 01/09/2010, Revision: 23, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 16:08

Human medicines European public assessment report (EPAR): Sycrest, asenapine, Date of authorisation: 01/09/2010, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Rozlytrek, entrectinib, Date of authorisation: 31/07/2020, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 15:53

Human medicines European public assessment report (EPAR): Rozlytrek, entrectinib, Date of authorisation: 31/07/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 15:35

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Zokinvy, lonafarnib, Date of authorisation: 18/07/2022, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 15:00

Human medicines European public assessment report (EPAR): Zokinvy, lonafarnib, Date of authorisation: 18/07/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 37, Status: Authorised

Submitted by Anonymous (not verified) on 3 November 2026 - 14:35

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 37, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More